Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05950139 · ClinicalTrials.gov registry record · Phase 1
Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC
A Phase 1 study of NSCLC Stage IV and ALK Fusion Protein Expression, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT05950139 is a Phase 1 study of NSCLC Stage IV and ALK Fusion Protein Expression that is actively recruiting participants, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 12 participants, below the 121-participant average among 6 other NSCLC Stage IV trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05950139, a Phase 1 study of NSCLC Stage IV and ALK Fusion Protein Expression, is actively recruiting participants, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the safety of a cancer peptide vaccine to prevent or delay acquired resistance in advanced ALK+ lung cancer patients currently on ALK targeted therapy.
Conditions Studied
Interventions
- BIOLOGICAL Peptide vaccine
Study Locations (1)
Maryland
- Johns Hopkins University - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2024-05-13 |
| Est. Completion | 2029-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05950139
The ClinicalTrials.gov registry entry for NCT05950139 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 121-participant average among 6 other NSCLC Stage IV trials with a reported enrollment target (90% lower). The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with NSCLC Stage IV appearing as the primary indexed condition, and to 1 intervention - of which Peptide vaccine is the first listed.
NCT05950139 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT05950139 about?
NCT05950139 is a clinical study titled "Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC". The purpose of this study is to evaluate the safety of a cancer peptide vaccine to prevent or delay acquired resistance in advanced ALK+ lung cancer patients currently on ALK targeted therapy.
What is the current status of trial NCT05950139?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2024-05-13. Estimated completion is 2029-07.
What conditions does trial NCT05950139 study?
This clinical trial studies the following conditions: NSCLC Stage IV, ALK Fusion Protein Expression.
What interventions are being tested in trial NCT05950139?
The interventions under investigation include: Peptide vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT05950139?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05950139 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for NSCLC Stage IV
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC
RECRUITING · Phase 1
-
ResQ201A: Clinical Trial Of N-803 Plus TISLELIZUMAB And DOCETAXEL Versus DOCETAXEL Monotherapy In Participants With Advanced Or Metastatic Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC
RECRUITING
-
A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Plasma-Adapted First-Line Pembro In NSCLC
ACTIVE NOT RECRUITING · Phase 2
-
Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.